Antibiotics to treat highly resistant enterococcus
Vancomycin-resistant enterococcus (VRE) is a leading cause of hospital-acquired infections in the U.S. There is an unmet need for new treatments of VRE, as infected patients frequently exhaust treatment options when fighting bacterial resistance.
Researchers at Purdue University have developed small molecules to combat drug-resistant enterococcus. These acetazolamide analogs demonstrated efficacy in two VRE animal models and possessed increased potency compared to linezolid, the current standard of care. Additionally, they were shown in vivo to selectively target VRE without harming the normal gut microbiota. The application for these compounds is for the treatment of drug-resistant enterococcus.